Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Estudio de fase 1//2, abierto y de aumento escalonado de la dosis para determinar la seguridad, tolerabilidad y la eficacia de BMN 331, un gen de transferencia de SERPING1 humano mediada por el vector del virus adenoasociado (AAV), en pacientes con angioedema hereditario (AEH) debido a carencia del inhibidor de la esterasa C1 (INH-C1) humano

Contact
  • Protocol code: BMN-331-201
  • EudraCT code: 2021-003603-18
  • Pathology: Malformacions congènites, deformitats i anomalies cromosòmiques
  • Principal investigator:  Guilarte Clavero, Mar
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Fase I
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de mitapivat en sujetos pediátricos con deficiencia de piruvato cinasa que reciben transfusiones con regularidad, seguido de un periodo de extensión abierto de 5 años

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

ESTUDIO DE FASE Ib, DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO Y MULTICÉNTRICO PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD Y LA FARMACOCINÉTICA DE DOSIS ASCENDENTES MÚLTIPLES DE RO7303509 EN PACIENTES CON ESCLEROSIS SISTÉMICA

Contact
  • Protocol code: GA43360
  • EudraCT code: 2021-004578-68
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Guillen Del Castillo, Alfredo
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Fase I
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio en fase III doble ciego, aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de ELX/TEZ/IVA en sujetos con fibrosis quística de 6 años o más con una mutación de CFTR no F508del que responde a ELX/TEZ/IVA

Contact
  • Protocol code: VX21-445-124
  • EudraCT code: 2021-005320-38
  • Pathology: Malalties del sistema respiratori
  • Principal investigator:  Álvarez Fernandez, Antonio
  • Research group:  Pneumologia
  • Service: Pneumologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de erenumab en niños (de 6 a < 12 años) y adolescentes (de 12 a < 18 años) con migraña episódica (OASIS PEDIATRIC [EM])

Contact
  • Protocol code: 20150125
  • EudraCT code: 2017-002397-39
  • Pathology: Malalties del sistema nerviós
  • Principal investigator:  Pozo Rosich, Patricia
  • Research group:  Cefalea i dolor neurològic
  • Service: Neurologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Ensayo en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad del sibeprenlimab administrado por vía subcutánea en sujetos con nefropatía por inmunoglobulina AEnsayo del sibeprenlimab en el tratamiento de la nefropatía por inmunoglobulina A

Contact
  • Protocol code: MB-106 (417-201-00007)
  • EudraCT code: No aplica
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Soler Romeo, Maria Jose
  • Research group:  Nefrologia i trasplantament renal
  • Service: Nefrologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Tancat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Pauta de dosificación ajustable de brodalumab en comparación con el tratamiento estándar con brodalumab durante 52 semanas en pacientes con psoriasis en placas de moderada a grave y 120 kg de peso corporal

Contact
  • Protocol code: LP0160-1329
  • EudraCT code: 2017-004998-13
  • Pathology: Malalties de la pell i del teixit subcutani
  • Principal investigator:  Aparicio Español, Gloria
  • Service: Dermatologia
  • Phase: Fase IV
  • Recruiting: Open
  • Status: Tancat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Protocolo maestro para ensayos clínicos dirigido a macrotrombosis, microinmunotrombosis, hiperinflamación vascular e hipercoagulabilidad y el sistema renina-angiotensina-aldosterona (SRAA) en pacientes hospitalizados con COVID-19

Contact
  • Protocol code: ACTIV-4
  • EudraCT code: 2022-000715-31
  • Pathology: Certes malalties infeccioses i parasitàries
  • Principal investigator:  Burgos Cibrian, Joaquin
  • Research group:  Malalties infeccioses
  • Service: Infeccioses
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

BHV3000-407: Estudio en fase IV, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y tolerabilidad de rimegepant para la prevención de la migraña en adultos con antecedentes de respuesta inadecuada a medicamentos preventivos orales.

Contact
  • Protocol code: BHV3000-407
  • EudraCT code: 2022-001176-34
  • Pathology: Malalties del sistema nerviós
  • Principal investigator:  Pozo Rosich, Patricia
  • Research group:  Cefalea i dolor neurològic
  • Service: Neurologia
  • Phase: Fase IV
  • Recruiting: Open
  • Status: Tancat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de extensión multicéntrico, abierto y doble ciego, controlado con placebocon retirada aleatorizada, seguido de ciclos de tratamiento abierto de larga duraciónpara evaluar la eficacia, seguridad y tolerabilidad de remibrutinib (LOU064) enpacientes adultos con urticaria crónica espontánea que hayan completado losestudios anteriores de fase III de remibrutinib.

Contact
  • Protocol code: CLOU064A2303B
  • EudraCT code: 2022-001034-11
  • Pathology: Malalties de la pell i del teixit subcutani
  • Principal investigator:  Labrador Horrillo, Moisés
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Subscribe to